학술논문

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
Document Type
Article
Source
British Journal of Cancer. 5/22/2012, Vol. 106 Issue 11, p1779-1789. 11p.
Subject
*OVARIAN cancer treatment
*TRASTUZUMAB
*HER2 protein
*ANTINEOPLASTIC agents
*PROTEINS
*KINASES
*CELL proliferation
*APOPTOSIS
Language
ISSN
0007-0920
Abstract
Background:Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how these drugs mediate their response is not clearly understood.Methods:Transcriptome profiling was performed after 4 days of trastuzumab, pertuzumab and combination treatment in human ovarian cancer in vivo. Signalling pathways identified were validated and investigated in primary ovarian xenografts at the protein level and across a timeseries.Results:A greater number and variety of genes were differentially expressed by the combination of antibody therapies compared with either treatment alone. Protein levels of cyclin-dependent kinase inhibitors p21 and p27 were increased in response to both agents and further by the combination; pERK signalling was inhibited by all treatments; but only pertuzumab inhibited pAkt signalling. The expression of proliferation, apoptosis, cell division and cell-cycle markers was distinct in a panel of primary ovarian cancer xenografts, suggesting the heterogeneity of response in ovarian cancer and a need to establish predictive biomarkers.Conclusion:This first comprehensive study of the molecular response to trastuzumab, pertuzumab and combined therapy in vivo highlights both common and distinct downstream effects to agents used alone or in combination, suggesting that complementary pathways may be involved. [ABSTRACT FROM AUTHOR]